Skip to content

A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523301-15-00
Acronym
22967
Enrollment
94
Registered
2025-11-11
Start date
2025-12-17
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasodilatory shock

Interventions

None listed

Sponsors

Bayer AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026